Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?

Detalhes bibliográficos
Autor(a) principal: Pereira, Susana P.
Data de Publicação: 2009
Outros Autores: Pereira, Gonçalo C., Moreno, António J., Oliveira, Paulo J.
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/47549
Resumo: Mitochondrial toxicity has resulted in the withdrawal of several drugs from the market. One particular example is nefazodone, an anti-depressant withdrawn in the USA due to hepatoxicity caused by drug-induced mitochondrial dysfunction. Drug development and safety testing can involve the use of large numbers of laboratory animals, which, without a decisive pre-screening for mitochondrial toxicity, are often unable to pre-empt higher mortality rates in some patient groups. The use of isolated mitochondria as a screening tool for drug safety can decrease the number of laboratory animals used in pre-clinical studies, thus improving animal welfare and healthcare outcomes and costs. Novel techniques involving high-throughput methods can be used to investigate whether a molecule is a mitochondrial toxicant. Moreover, these screens are mechanistically-based, since the effects of the drug on oxidative phosphorylation, calcium homeostasis and mitochondrial genetics can be assessed. This review is intended to demonstrate that isolated mitochondrial fractions are suitable for predicting drug and general chemical safety in toxicological screenings, thus contributing to the refinement and reduction of animal use in laboratory research.
id RCAP_caa606b5c34f23876be2b4c0cc6cdaa7
oai_identifier_str oai:estudogeral.uc.pt:10316/47549
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?AnimalsCell FractionationDrug Evaluation, PreclinicalDrug-Related Side Effects and Adverse ReactionsHigh-Throughput Screening AssaysHumansMembrane Potential, MitochondrialMitochondriaMitochondrial Membrane Transport ProteinsModels, AnimalPermeabilityPredictive Value of TestsRisk AssessmentXenobioticsAnimal Testing AlternativesAnimals, LaboratoryMitochondrial toxicity has resulted in the withdrawal of several drugs from the market. One particular example is nefazodone, an anti-depressant withdrawn in the USA due to hepatoxicity caused by drug-induced mitochondrial dysfunction. Drug development and safety testing can involve the use of large numbers of laboratory animals, which, without a decisive pre-screening for mitochondrial toxicity, are often unable to pre-empt higher mortality rates in some patient groups. The use of isolated mitochondria as a screening tool for drug safety can decrease the number of laboratory animals used in pre-clinical studies, thus improving animal welfare and healthcare outcomes and costs. Novel techniques involving high-throughput methods can be used to investigate whether a molecule is a mitochondrial toxicant. Moreover, these screens are mechanistically-based, since the effects of the drug on oxidative phosphorylation, calcium homeostasis and mitochondrial genetics can be assessed. This review is intended to demonstrate that isolated mitochondrial fractions are suitable for predicting drug and general chemical safety in toxicological screenings, thus contributing to the refinement and reduction of animal use in laboratory research.2009-09info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/47549http://hdl.handle.net/10316/47549porPereira, Susana P.Pereira, Gonçalo C.Moreno, António J.Oliveira, Paulo J.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2021-10-11T11:09:23Zoai:estudogeral.uc.pt:10316/47549Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:53:38.364813Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
title Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
spellingShingle Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
Pereira, Susana P.
Animals
Cell Fractionation
Drug Evaluation, Preclinical
Drug-Related Side Effects and Adverse Reactions
High-Throughput Screening Assays
Humans
Membrane Potential, Mitochondrial
Mitochondria
Mitochondrial Membrane Transport Proteins
Models, Animal
Permeability
Predictive Value of Tests
Risk Assessment
Xenobiotics
Animal Testing Alternatives
Animals, Laboratory
title_short Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
title_full Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
title_fullStr Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
title_full_unstemmed Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
title_sort Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
author Pereira, Susana P.
author_facet Pereira, Susana P.
Pereira, Gonçalo C.
Moreno, António J.
Oliveira, Paulo J.
author_role author
author2 Pereira, Gonçalo C.
Moreno, António J.
Oliveira, Paulo J.
author2_role author
author
author
dc.contributor.author.fl_str_mv Pereira, Susana P.
Pereira, Gonçalo C.
Moreno, António J.
Oliveira, Paulo J.
dc.subject.por.fl_str_mv Animals
Cell Fractionation
Drug Evaluation, Preclinical
Drug-Related Side Effects and Adverse Reactions
High-Throughput Screening Assays
Humans
Membrane Potential, Mitochondrial
Mitochondria
Mitochondrial Membrane Transport Proteins
Models, Animal
Permeability
Predictive Value of Tests
Risk Assessment
Xenobiotics
Animal Testing Alternatives
Animals, Laboratory
topic Animals
Cell Fractionation
Drug Evaluation, Preclinical
Drug-Related Side Effects and Adverse Reactions
High-Throughput Screening Assays
Humans
Membrane Potential, Mitochondrial
Mitochondria
Mitochondrial Membrane Transport Proteins
Models, Animal
Permeability
Predictive Value of Tests
Risk Assessment
Xenobiotics
Animal Testing Alternatives
Animals, Laboratory
description Mitochondrial toxicity has resulted in the withdrawal of several drugs from the market. One particular example is nefazodone, an anti-depressant withdrawn in the USA due to hepatoxicity caused by drug-induced mitochondrial dysfunction. Drug development and safety testing can involve the use of large numbers of laboratory animals, which, without a decisive pre-screening for mitochondrial toxicity, are often unable to pre-empt higher mortality rates in some patient groups. The use of isolated mitochondria as a screening tool for drug safety can decrease the number of laboratory animals used in pre-clinical studies, thus improving animal welfare and healthcare outcomes and costs. Novel techniques involving high-throughput methods can be used to investigate whether a molecule is a mitochondrial toxicant. Moreover, these screens are mechanistically-based, since the effects of the drug on oxidative phosphorylation, calcium homeostasis and mitochondrial genetics can be assessed. This review is intended to demonstrate that isolated mitochondrial fractions are suitable for predicting drug and general chemical safety in toxicological screenings, thus contributing to the refinement and reduction of animal use in laboratory research.
publishDate 2009
dc.date.none.fl_str_mv 2009-09
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/47549
http://hdl.handle.net/10316/47549
url http://hdl.handle.net/10316/47549
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133822924619776